Gastro-oesophageal reflux disease: Beyond proton pump inhibitor therapy

Drugs

Volumn 71, Issue 18, 2011, Pages 2381-2389

  Hershcovici, Tiberiu ^a   Fass, Ronnie ^b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Gastro oesophageal reflux; Gastrokinetics; Histamine H2 receptor antagonists; Proton pump inhibitors

Indexed keywords

ADX 10059; ARBACLOFEN PLACARBIL; AZD 1386; AZD 8065; BACLOFEN; CHOLECYSTOKININ; DOMPERIDONE; DRONABINOL; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITOPRIDE; LESOGABERAN; LOXIGLUMIDE; METABOTROPIC RECEPTOR ANTAGONIST; METOCLOPRAMIDE; MOSAPRIDE; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; PUMOSETRAG; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ACUPRESSURE; ANXIETY; ARTICLE; BACTERIAL OVERGROWTH; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTROACUPUNCTURE; FRAGILITY FRACTURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIP FRACTURE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPERPARATHYROIDISM; LIVER FAILURE; LIVER TOXICITY; LOWER ESOPHAGUS SPHINCTER; MENTAL DISEASE; MICROSCOPIC COLITIS; MINERAL DEFICIENCY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; REFLUX ESOPHAGITIS; SIDE EFFECT; SPINE FRACTURE; STOMACH ACID SECRETION; STOMACH FUNDOPLICATION; STOMACH GLAND POLYP; STOMACH SURGERY; TACHYPHYLAXIS; VITAMIN DEFICIENCY; WRIST FRACTURE;

EID: 82955240590     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11597300-000000000-00000     Document Type: Article

References (63)

1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May; 54 (5): 710-7 (Pubitemid 40559260)
2. Locke 3rd GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a populationbased study in Olmsted County, Minnesota. Gastroenterology 1997 May; 112 (5): 1448-56 (Pubitemid 27181367)
3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976 Nov; 21 (11): 953-6
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002 May; 122 (5): 1500-11 (Pubitemid 34465190)
5. Chiba N, De Gara CJ,Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 Jun; 112 (6): 1798-810 (Pubitemid 27240763)
6. Fass R, Shapiro M, Dekel R, et al. Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease. Where next? Aliment Pharmacol Ther 2005 Jul 15; 22 (2): 79-94 (Pubitemid 41039696)
7. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol 2010 Jul; 26 (4): 389-94
8. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004 Oct 27; 292 (16): 1955-60 (Pubitemid 39411203)
9. Dial S, Alrasadi K,Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004 Jul 6; 171 (1): 33-8 (Pubitemid 38925116)
10. Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010 Nov; 32 (9): 1124-8
11. Lombardo L, FotiM, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010 Jun; 8 (6): 504-8
12. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010 Oct; 139 (4): 1115-27
13. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009 Mar; 104 Suppl. 2: S5-9
14. Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011 Aug 8; 171 (15): 1391-2
15. Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009 Jul; 137 (1): 80-7
16. Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010 Jul; 105 (7): 1531-7
17. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? AmJGastroenterol 2010 Jan; 105 (1): 34-41
18. Fass R, Hixson LJ, Ciccolo ML, et al. Contemporary medical therapy for gastroesophageal reflux disease. Am Fam Physician 1997 Jan; 55 (1): 205-12, 17-8 (Pubitemid 27034713)
19. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000 Feb; 118 (2 Suppl. 1): S9-31 (Pubitemid 30094433)
20. Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005 Jul 14; 11 (26): 4067-77
21. Johnson NJ, Boyd EJ, Mills JG, et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989 Jun; 3 (3): 259-66 (Pubitemid 20113027)
22. Kahrilas PJ, Fennerty MB, Joelsson B. High-versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999 Jan; 94 (1): 92-7 (Pubitemid 29063450)
23. Peghini PL,Katz PO, CastellDO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115 (6): 1335-9 (Pubitemid 28545982)
24. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122 (3): 625-32 (Pubitemid 34173813)
25. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007 Dec; 5 (12): 1385-91 (Pubitemid 350181597)
26. Zhang Q, Lehmann A, Ridga R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastrooesophageal reflux disease. Gut 2002; 50 (1): 19-24 (Pubitemid 34028297)
27. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodenogastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003 Oct; 52 (10): 1397-402 (Pubitemid 37176716)
28. VelaMF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003 Jan; 17 (2): 243-51 (Pubitemid 36174255)
29. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010 Jun; 105 (6): 1266-75
30. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010 Aug; 139 (2): 409-17
31. BoeckxstaensGE, BeaumontH,Hatlebakk JG, et al. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy [abstract]. Gastroenterology 2009 May; 136 (5 Suppl. 1): A-436
32. Frisby CL,Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005 Sep; 129 (3): 995-1004 (Pubitemid 41242690)
33. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009 Sep; 58 (9): 1192-9
34. Partosoedarso ER, Abrahams TP, Scullion RT, et al. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003 Jul 1; 550 (Pt 1): 149-58 (Pubitemid 36869276)
35. Beaumont H, Jensen J, Carlsson A, et al. Effect of delta9- tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009 Jan; 156 (1): 153-62
36. Scarpellini E, Blondeau K, Boecxstaens V, et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol Ther 2011 Mar; 33 (6): 730-7
37. Hershcovici T, Fass R. Transient lower oesophageal sphincter relaxation reducers: have we hit a brick wall? Aliment Pharmacol Ther 2011 Jun; 33 (11): 1256-7; author reply 7-8
38. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135 (4): 1383-91
39. Masci E, Testoni PA, Passaretti S, et al. Comparison of ranitidine, domperidone maleate and ranitidine+domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985; 11 (10): 687-92 (Pubitemid 16203083)
40. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005 Jul 21; 11 (27): 4210-4 (Pubitemid 41086873)
41. Scarpellini E, Vos R, Blondeau K, et al. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther 2011 Jan; 33 (1): 99-105
42. RuthM,Hamelin B, RohssK, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 Jan; 12 (1): 35-40 (Pubitemid 28057402)
43. Cho YK, Choi MG, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006 Apr; 40 (4): 286-92 (Pubitemid 44309518)
44. Boulant J, Fioramonti J, Dapoigny M, et al. Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distention in dogs. Gastroenterology 1994 Oct; 107 (4): 1059-66 (Pubitemid 24294568)
45. Zerbib F, Bruley Des Varannes S, Scarpignato C, et al. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol 1998 Dec; 275 (6 Pt 1): G1266-73
46. Choung RS, Ferguson DD, Murray JA, et al. A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebocontrolled pharmacodynamic study. Aliment Pharmacol Ther 2008 Mar 1; 27 (5): 404-11
47. Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011 May; 33 (10): 1113-22
48. del Genio G, Tolone S, del Genio F, et al. Total fundoplication controls acid and nonacid reflux: evaluation by pre-and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008 Nov; 22 (11): 2518-23
49. Kahrilas PJ. Surgical therapy for reflux disease. JAMA 2001 May 9; 285 (18): 2376-8 (Pubitemid 32424107)
50. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011 May 18; 305 (19): 1969-77
51. Schwartz MP, Smout AJ. Review article: the endoscopic treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007 Dec; 26 Suppl. 2: 1-6 (Pubitemid 350233318)
52. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001 May 9; 285 (18): 2331-8 (Pubitemid 32424101)
53. Louis H, Deviere J. Ensocopic-endoluminal therapies: a critical appraisal. Best Pract Res Clin Gastroenterol 2010 Dec; 24 (6): 969-79
54. Cadiere GB, Buset M, Muls V, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008 Aug; 32 (8): 1676-88
55. Hoppo T, Immanuel A, Schuchert M, et al. Transoral incisionless fundoplication 2.0 procedure using EsophyX for gastroesophageal reflux disease. J Gastrointest Surg 2010 Dec; 14 (12): 1895-901
56. Kim MS, Holloway RH, Dent J, et al. Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux in dogs. Gastrointest Endosc 2003 Jan; 57 (1): 17-22 (Pubitemid 36236793)
57. Arts J, Sifrim D, Rutgeerts P, et al. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 2007 Sep; 52 (9): 2170-7 (Pubitemid 47246518)
58. Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003 Sep; 125 (3): 668-76 (Pubitemid 37070685)
59. Bonavina L, Saino GI, Bona D, et al. Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg 2008 Dec; 12 (12): 2133-40
60. Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one-and 2-year results of a feasibility trial. Ann Surg 2010 Nov; 252 (5): 857-62
61. Zou D, Chen WH, Iwakiri K, et al. Inhibition of transient lower esophageal sphincter relaxations by electrical acupoint stimulation. Am J Physiol Gastrointest Liver Physiol 2005 Aug; 289 (2): G197-201 (Pubitemid 41022744)
62. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007 Nov 15; 26 (10): 1333-44 (Pubitemid 350045612)
63. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2008; 27 (6): 473-82 (Pubitemid 351300853)